Summary
The U.S. Food and Drug Administration (FDA) is facing a range of challenges, including political and scientific pressures, staff changes, and criticism of its approval processes. The FDA recently received backlash for comments about an autism treatment and faced leadership changes with the resignation of a key official. The Trump administration is focusing on autism, leading to debates in the healthcare community.
Key Facts
- The FDA is under political, scientific, legal, and operational pressure.
- There is controversy over an autism treatment endorsed by the White House but lacking strong evidence.
- The FDA approved leucovorin for a rare genetic disorder but not for autism.
- Dr. Peter Marks resigned from the FDA, raising concerns about changes in vaccine policy.
- President Trump and HHS Secretary Kennedy prioritize autism research, causing debate.
- The FDA faces scrutiny over its drug approval process and recent staff cuts.
